Novel strategy for the use of leptin for obesity therapy.
Authors:
- 13 September 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 11 (12) , 1677-1685
Abstract
Introduction: Obesity is a chronic disease and a major global health challenge. Apart from bariatric surgery, which is costly and not without risk, there are currently no successful long-term treatment options for obesity. The history of pharmacological agents for obesity has been turbulent with many examples of drugs being removed from the market due to significant side effects. Orlistat and sibutramine (the latest drugs on the market) provide only modest weight loss and are both associated with high attrition rates due to intolerable side effects. Furthermore, sibutramine was recently withdrawn from the market. There is a need for the development of safe and efficacious drug treatments for obesity. Areas covered: This review covers the history of leptin therapy as an orphan drug, leptin-replacement therapy as a treatment for obesity, preclinical studies showing the efficacy of leptin/amylin combination and finally, the very promising early clinical findings using pramlintide/meteleptin combination therapy in overweight to obese individuals. Expert opinion: Combination pharmacological therapy, such as pramlintide/metreleptin, for the treatment of obesity is very promising and is supported by encouraging weight loss results and improvement in metabolic makers in early-phase clinical studies. However, the latest randomized clinical trial on pramlintide/metreleptin was recently stopped due to safety concerns.Keywords
This publication has 68 references indexed in Scilit:
- The Fall in Leptin Concentration Is a Major Determinant of the Metabolic Adaptation Induced by Caloric Restriction Independently of the Changes in Leptin Circadian RhythmsThe Journal of Clinical Endocrinology & Metabolism, 2011
- Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric dietEuropean Journal of Endocrinology, 2011
- Effects of chronic weight perturbation on energy homeostasis and brain structure in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Leptin is an effective treatment for hypothalamic amenorrheaProceedings of the National Academy of Sciences, 2011
- Leptin Replacement Prevents Weight Loss-Induced Metabolic Adaptation in Congenital Leptin-Deficient PatientsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity PharmacotherapyObesity, 2009
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophyMetabolism, 2007
- Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiencyJournal of Clinical Investigation, 2002
- Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinaseNature, 2002